Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures
Information source: University of Pittsburgh
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Isolate; Linezolid
Phase: N/A
Status: Completed
Sponsored by: University of Pittsburgh Official(s) and/or principal investigator(s): Brian Potoski, Pharm D, Principal Investigator, Affiliation: University of Pittsburgh
Summary
The study will help in identifying the best empiric antibiotic option for Linezolid
resistant Vancomycin-resistant Enterococci (VRE) infections. This research is important
because it allows the determination of resistance rates to antibiotics that may not be
frequently tested to by the clinical microbiology laboratory at UPMC-Presbyterian. It also
will provide antibiotic minimum inhibitory concentrations (MICs) for these pathogens which
may help in identifying the best empiric antibiotic option for Linezolid-resistant VRE
infections.
Clinical Details
Official title: Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: dead or alive
Detailed description:
After 20 linezolid-resistant VRE isolates are identified, genetic relatedness will be
determined using a method known as Pulse-field gel electrophoresis (PFGE). No patient
related data will accompany these isolates, nor will any related identifiers. These
isolates will be tested using standardized susceptibility methods. We will then grow each
isolate and test via approved laboratory standards (E-test, AB Biodisk, Stockholm, Sweden)
to the drug linezolid. Those determined to be resistant using this approved methodology will
be saved until 20 isolates are identified. For resistant isolates found, analytical and
molecular techniques will be performed to determine the mechanisms of resistance and whether
resistant isolates are coming from a single source/being transmitted from person to person.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Dr. Harrison's laboratory collected the rectal surveillance isolates for infection
control purposes. The isolates will be from January 1, 2006 to December 31, 2006.
Locations and Contacts
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, United States
Additional Information
Starting date: April 2007
Last updated: December 5, 2014
|